To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Stopped Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.

Conditions

• Fatigue
• Locally Advanced or Metastatic Breast Cancer

Interventions

• DRUG: Reparixin
• DRUG: Placebo

Sponsor

Dompé Farmaceutici S.p.A